Direct comparison of different coating matrix on the hepatic differentiation from adipose-derived stem cells.
Zhang X., Dong J.
Animal Study, published in Biochem Biophys Res Commun (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biochem Biophys Res Commun (2014)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 25446084
- DOI
- 10.1016/j.bbrc.2014.11.004
- Citations
- 25
Abstract (original English)
Various extracellular matrix components were employed as coating materials to promote hepatic differentiation from ADSCs. However, no consensus was achieved about the optimal coating matrix due to the lack of direct comparison among different coating matrix. In this study, several coating extracellular matrixs were used for hepatic differentiation of ADSCs and direct comparison between them was performed. We demonstrated that liver DCM as coating matrix could significantly enhance the hepatic differentiation from ADSCs compared with collagen, fibronectin and Matrigel both in the presence and absence of GFs, including enhanced hepatocyte-specific genes expression, hepatocyte related protein secretion with improved liver functions. And the differentiated cells also exhibited the characteristics of mature hepatocytes. In conclusion, the study proved an effective hepatic-inducing method and indicated that DCM could promote the differentiation of ADSCs into hepatocyte-like cells, which demonstrates feasibility of liver DCM as a bio-scaffold for liver regenerative medicine and tissue engineering.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.